Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125671571 | 12567157 | 1 | I | 20160712 | 20160718 | 20160718 | EXP | US-MYLANLABS-2016M1029520 | MYLAN | LEE SY, BRAUNEIS D, STERN L, SANCHORAWALA V. OPTIMAL DOSING OF HIGH-DOSE MELPHALAN PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A PATIENT WITH AL AMYLOIDOSIS AND A SOLITARY KIDNEY. HEMATOL-ONCOL-STEM-CELL-THER 2016;9(2):86-88. | 0.00 | Y | 0.00000 | 20160718 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125671571 | 12567157 | 1 | PS | MELPHALAN | MELPHALAN | 1 | Intravenous (not otherwise specified) | 200 MG/M2 OVER 2 DAYS | U | U | 90270 | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125671571 | 12567157 | 1 | Amyloidosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125671571 | 12567157 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125671571 | 12567157 | Anaemia | |
| 125671571 | 12567157 | Febrile neutropenia | |
| 125671571 | 12567157 | Neutropenia | |
| 125671571 | 12567157 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |